Spyre Therapeutics (SYRE)'s 30-day implied volatility (IV30) was 71.1% at the close on November 2, 2026, down from 72.7% the day before, against a 52-week range of 45.4% to 114.2%. Its 20-day historical volatility was 63.6%.
Data as of November 2, 2026.